Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)345.89K

Market Cap

kr131.45M

Enterprise Valuekr97.59

Total Cash (Recent Filing)kr21.09M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.42

Next Earnings

Oct 22, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding126,392,960

10 Day Avg. Volume370,539

30 Day Avg. Volume345,887

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.7

Revenue Forecast (FY)kr254.00M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free balance sheet reduces refinancing pressure and interest obligations, giving NextCell greater financial flexibility while it develops its therapies. This is a durable strength, although the declining equity base limits the protection provided by low leverage.

Longer-term Revenue GrowthRevenue growth across the TTM and preceding annual periods indicates that NextCell is generating some commercial or development-related demand despite its early-stage profile. Sustained growth could provide a foundation for improved operating leverage if margins eventually recover.

Proprietary Cell-therapy PlatformA proprietary stem-cell platform combined with MSC therapy and cell-banking capabilities gives NextCell an integrated position across development and supporting services. These capabilities may support multiple programs and partnerships, although commercialization remains dependent on clinical and financial execution.

Bears Say

Sustained Cash BurnPersistently negative operating and free cash flow, worsening in the TTM, shows that the business is not self-funding its operations. Continued cash burn can require additional financing, potentially diluting shareholders and constraining investment in clinical development.

Deeply Negative ProfitabilityLarge gross and net losses indicate that current products and activities do not yet cover their cost base. The absence of demonstrated operating leverage makes profitability highly dependent on successful development, commercialization, and eventual improvement in gross margins.

Eroding Equity BaseThe substantial reduction in equity reflects the cumulative effect of ongoing losses and cash consumption. Even without debt, a shrinking capital base reduces resilience and may increase reliance on future equity funding to sustain operations and advance therapies.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr131.45M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Oct 22, 2026 which is in 44 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Aug 27, 2026. The company reported -kr0.092 earnings per share for the quarter.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 126,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report. Following the earnings report the stock price went down -1.318%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.